The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Moderna (MRNA) is scheduled to announce Q3 earnings results on November 6, before market open, with analysts’ consensus ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system ...

Researchers found that COVID-19 mRNA vaccines significantly increased survival in lung and skin cancer patients undergoing ...

People with advanced lung or skin cancer who were taking certain immunotherapy drugs lived substantially longer if they also ...

University of Florida researchers found that advanced lung and skin cancer patients lived “significantly longer” after ...

President Donald Trump’s physician, Dr. Sean P. Barbabella, announced that after conducting a battery of tests, he found that ...